Alpha Cognition Secures U.S. Patent for Alzheimer’s Drug
Company Announcements

Alpha Cognition Secures U.S. Patent for Alzheimer’s Drug

Story Highlights

Alpha Cognition Inc (TSE:ACOG) has released an update.

Alpha Cognition Inc. has received a Notice of Allowance from the USPTO for its patented Alzheimer’s drug, ZUNVEYL, which strengthens its intellectual property protection in the U.S. until 2044. This milestone supports the company’s mission to develop innovative therapies for neurodegenerative diseases.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Plans Nasdaq Listing and $25M Offering
TipRanks Canadian Auto-Generated NewsdeskAlpha Cognition Inc. Appoints New Finance VP
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App